[go: up one dir, main page]

WO2017209069A1 - Article absorbant - Google Patents

Article absorbant Download PDF

Info

Publication number
WO2017209069A1
WO2017209069A1 PCT/JP2017/019964 JP2017019964W WO2017209069A1 WO 2017209069 A1 WO2017209069 A1 WO 2017209069A1 JP 2017019964 W JP2017019964 W JP 2017019964W WO 2017209069 A1 WO2017209069 A1 WO 2017209069A1
Authority
WO
WIPO (PCT)
Prior art keywords
absorbent article
article according
density
absorbent
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/019964
Other languages
English (en)
Japanese (ja)
Inventor
暁 湯山
祐一 廣瀬
良輔 山崎
雅義 阿部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Publication of WO2017209069A1 publication Critical patent/WO2017209069A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/531—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad
    • A61F13/532—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/531—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad
    • A61F13/532—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad
    • A61F13/533—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad having discontinuous areas of compression

Definitions

  • the present invention relates to an absorbent article for menstrual blood absorption.
  • Patent Document 1 discloses a menstrual band including an absorbent pad containing a salt of multivalent ions.
  • Patent Document 2 discloses a napkin containing a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent.
  • Patent Document 3 proposes a personal care absorbent article containing a triblock polymer or polycation containing polypropylene oxide and polyethylene oxide as a fluid treatment material.
  • the present invention includes a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorber disposed between the two sheets, and a longitudinal direction along the wearer's front-rear direction and a transverse direction perpendicular to the longitudinal direction.
  • the present invention provides an absorbent article for menstrual blood absorption. Further, according to the present invention, a first high-density portion is formed extending in the vertical direction on each side of a center line extending in the vertical direction X by dividing the absorbent article into two equal to the horizontal direction Y.
  • the present invention provides an absorbent article in which a hemagglutinating agent is disposed on the absorbent body in the region between the density portions.
  • the absorber has a second high density portion formed in a region between the first high density portions, and the first and second high density portions have a density of the absorber of the first density.
  • the present invention provides an absorbent article that has a higher density than the density in a portion other than the first and second high-density portions.
  • FIG. 1 is a plan view of a sanitary napkin which is an embodiment of the absorbent article of the present invention.
  • 2 is a cross-sectional view taken along line II-II in FIG. 3 is a cross-sectional view taken along line III-III in FIG.
  • FIG. 4 is an enlarged plan view of a part of the skin facing surface of the sanitary napkin shown in FIG. 1, and is an explanatory view of the arrangement of the second high density portions (dents).
  • FIG. 5 is an explanatory view of the function and effect of the present invention, and is a view showing a cross section corresponding to FIG.
  • FIG. 6 is a plan view of a sanitary napkin which is another embodiment of the absorbent article of the present invention.
  • FIG. 7 is a plan view of a sanitary napkin which is still another embodiment of the absorbent article of the present invention.
  • Patent Documents 1 and 4 do not describe any structure for improving the blood absorption rate or improving the absorption amount, except that a water-soluble metal compound is used as a blood cell coagulant.
  • the absorbent articles described in Patent Literature 2 and Patent Literature 3 describe that a fluid treatment agent containing a polycation can be used, only data on nonionic treatment materials is actually disclosed.
  • due to a decrease in liquid permeability due to blood aggregates at the portion facing the excretion spot of the absorbent article absorption of blood into the absorber is hindered, and it takes time to absorb the blood. It is also disadvantageous in that the amount of absorbed blood is reduced.
  • an object of the present invention is to provide an absorbent article in which the effect of improving the absorption performance by the hemagglutinating agent is expressed more effectively.
  • a sanitary napkin 1 (hereinafter also referred to as “napkin 1”) according to an embodiment of the present invention includes a liquid-permeable top sheet 2 and a liquid-impermeable back sheet as shown in FIGS. 3 and a liquid retaining absorbent 4 disposed between the two sheets 2 and 3.
  • the top sheet 2, the absorber 4 and the back sheet 3 are integrated to form an absorbent main body 5.
  • Side leakproof sheets 6 are arranged on the surface sheet 2 side on both sides in the longitudinal direction of the absorbent main body 5.
  • the side leak-proof sheet 6 has a free end 61 that is not joined to the top sheet 2 and a fixed end 62 that is joined to the top sheet 2, and is used between the fixed end 62 and the free end 61 when used. Forms a leak-proof pocket (not shown) that separates from the top sheet 2 and prevents lateral leakage to the side.
  • a main body adhesive portion (not shown) used for fixing to the crotch portion of the shorts is provided on the non-skin facing surface of the absorbent main body 5.
  • the napkin 1 has a pair of wing portions 7 on both side portions in the longitudinal direction X. On the surface of the pair of wing portions 7 on the back sheet 3 side, a wing adhesive portion (not shown) used for fixing the crotch portion of the shorts to the non-skin facing surface is provided.
  • the napkin 1 includes an excretory part facing part B that is disposed to face the excretion part (such as the vaginal opening) of the wearer when worn, and the abdomen (front side) of the wearer than the excretion part facing part B ) And a rear portion C disposed closer to the wearer's back side (rear side) than the excretory portion facing portion B.
  • the napkin 1 has a longitudinal direction X corresponding to the wearer's front-rear direction and a transverse direction Y orthogonal to the longitudinal direction X. That is, the napkin 1 is divided into the front part A, the excretion part opposing part B, and the rear part C in this order in the vertical direction X.
  • a skin opposing surface is a surface in the napkin 1 or its component (for example, surface sheet 2, absorptive core 41) orient
  • the facing surface is a surface of the napkin 1 or its constituent members that is directed to the side opposite to the skin side (usually the clothing side) when the napkin 1 is worn. The same applies to absorbent articles other than the napkin 1 for absorbing menstrual blood.
  • the excretory part facing part B is a wing in the longitudinal direction X of the absorbent article when it has a so-called wing part like the napkin 1 of the present embodiment.
  • two folding lines that cross the absorbent article in the transverse direction Y which are generated when the absorbent article is folded into a tri-fold individual form.
  • region enclosed by the 1st folding line and the 2nd folding line is counted from the front end of the longitudinal direction X of this absorbent article.
  • the top sheet 2 covers the entire area of the skin 4 of the absorbent body 4, and the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4.
  • the surface sheet 2 and the back surface sheet 3 are joined to each other at the extended portions from both end edges in the longitudinal direction X of the absorber 4.
  • the back sheet 3 and the side leak-proof sheet 6 are joined to each other at portions extending outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorber 4. In this way, the absorbent body 4 is sandwiched between the top sheet 2 and the back sheet 3.
  • any joining means such as an adhesive, heat sealing, ultrasonic sealing or the like is used.
  • the napkin 1 of the present embodiment has a pair of side leakage preventing grooves 81, 81 extending in the longitudinal direction X and a pair of side leakage preventing grooves 81, 81 on the skin facing surface of the napkin 1.
  • the front leakage prevention groove 82 for connecting the end portions of the pair of side leakage prevention grooves 81, 81 on the front portion A side
  • the rear leakage prevention groove 83 for connecting the end portions of the pair of side leakage prevention grooves 81, 81 on the rear portion C side.
  • An annular leak-proof groove 8 is formed.
  • each of the pair of side leakage preventing grooves 81 has a plan view shape in which three arcuate portions that are convexly curved outward in the lateral direction Y are connected in the longitudinal direction X.
  • the front leakage prevention groove 82 has an arcuate plan view shape curved convexly toward the front
  • the rear leakage prevention groove 83 has an arcuate plan view shape curved convexly toward the rear. Yes.
  • Each of the pair of side leakage preventing grooves 81 extends in the longitudinal direction X of the napkin 1 on each side of the center line CL that bisects the napkin 1 (absorbent article) in the lateral direction Y and extends in the longitudinal direction X. Yes.
  • the side leakage preventing groove 81 is a first high density portion.
  • the side leak-proof groove 81 that is the first high-density portion at least the density of the absorber 4, particularly the absorbent core 41, is the side leak-proof groove 81 that is the first high-density portion and the second high-density described later. It is higher than the density of the same member in parts other than the hollow 86 which is a part.
  • the density of the absorber 4 that overlaps the side leak-proof groove 81 is other than the side leak-proof groove 81 and other than the depression 86.
  • the density is higher than the density of the absorbent body 4 at the site.
  • the density of the absorbent core 41 in the portion overlapping the side leakage preventing groove 81 is other than the side leakage preventing groove 81 and other than the depression 86.
  • the density is higher than the density of the absorbent core 41 in the part which is the part.
  • the density of the portion forming the side leakage preventing groove 81 in the topsheet 2 is a portion other than the side leakage preventing groove 81 and The density is higher than the density of the topsheet 2 in the region where the depression 86 is not formed.
  • the pair of side leakage preventing grooves 81, 81 preferably extend in the vertical direction X in the excretory part facing part B, and further extend in the vertical direction X on both sides sandwiching the excretion spot part P. preferable.
  • the side leakage prevention groove 81 preferably extends from the excretory part facing part B to the front part A or the rear part C. As shown in FIG. 1, the front part A, the excretion part facing part B, and More preferably, it extends over the rear part C.
  • the end part by the side of the front part A is connected by the front leak-proof groove 82 which passes a front side from the excretion spot part P, and a pair of side leak-proof groove 81,81 is excreted.
  • the excretion spot part P is a part where the menstrual blood is directly supplied facing the wearer's liquid excretion part (vagina opening) when using an absorbent article such as the napkin 1, It is located in the center part of the vertical direction X and the horizontal direction Y of the excretion part opposing part B mentioned above.
  • the excretion spot portion P of the napkin 1 has a major axis 3 cm along the center line extending in the longitudinal direction X and equally dividing the napkin 1 in the width direction (same as the transverse direction Y), and a minor axis 2 cm along the lateral direction Y. It has an oval shape.
  • the center point of the excretion spot portion P is preferably substantially located on the bisector of the wing portion.
  • “almost located” means that the bisector may be deviated by 15 mm forward and rearward from the bisector, but even in that case, it falls within the excretion spot part P excretion part facing part B. It exists.
  • the annular leak-proof groove 8 has a skin-facing surface side of the absorbent body 4 in a groove shape together with the surface sheet 2 in any of the side leak-proof groove 81, the front leak-proof groove 82, and the rear leak-proof groove 83,
  • the absorber 4 has portions where the leak-proof grooves 81, 82, and 83 are formed, as compared to the portions of the absorber 4 that are located on both sides of the leak-proof grooves 81, 82, and 83, respectively. And consolidated.
  • the annular leak-proof groove 8 can be formed by, for example, applying embossing with pressurization or heating and pressurization to the superposed sheet of the top sheet 2 and the absorber 4.
  • the napkin 1 has depressions 86 formed in a region D between the side leakage prevention grooves 81 in a plan view of the napkin 1.
  • This depression 86 is the second high-density portion.
  • the skin facing surface side of the absorbent body 4 is recessed in a concave shape together with the surface sheet 2, as shown in FIG. 3.
  • the dent 86 that is the second high-density portion at least the density of the absorbent body 4, particularly the absorbent core 41, is other than the side leakage prevention groove 81 that is the first high-density portion and the dent 86 that is the second high-density portion.
  • the density is higher than the density of the same member in the part.
  • the density of the absorber 4 in a portion overlapping the dent 86 is a part other than the side leakage prevention groove 81 and a part other than the dent 86 in the part.
  • the density is higher than the density.
  • the density of the absorbent core 41 in the portion overlapping with the depression 86 is absorbed in a portion other than the side leakage prevention groove 81 and a portion other than the depression 86.
  • the density is higher than the density of the conductive core 41.
  • the density of the part which the surface sheet 2 also dents with the skin opposing surface of the absorber 4 and forms the dent 86 is parts other than the side leak-proof groove 81.
  • the density is higher than the density of the topsheet 2 in the portion where the recess 86 is not formed.
  • each of the second high-density portions or the depressions 86 has a length Lx along the longitudinal direction X of the napkin 1 (absorbent article), preferably a length Ly along the lateral direction Y, preferably 1. It is 2 times or more and 30 times or less, more preferably 2 times or more and 4 times or less.
  • Each of the second high-density portions or the individual depressions 86 has a length Lx along the longitudinal direction X that is preferably not less than 1/1000 and not more than 1/5 of the length of the first high-density portion 81 in the same direction. More preferably, it is 1/100 or more and 1/50 or less.
  • each second high-density portion or depression 86 is preferably 0.5 mm 2 or more, more preferably 2 mm 2 or more, and preferably 15 mm 2 or less, more preferably 5 mm 2 or less. preferably 15 mm 2 or less 0.5 mm 2 or more, more preferably 5 mm 2 or less 2 mm 2 or more.
  • the dents 86 as the second high-density portions are arranged with a plurality of dents 86 aligned in the vertical direction X as shown in FIG. More specifically, the recess rows R6 in which the recesses 86 are arranged in series in the vertical direction X are formed so as to be formed in a plurality of rows in the horizontal direction Y. Further, the interval P2 between the adjacent depression rows R6 and R6 is wider than the interval P1 between the depressions 86 in the depression row R6.
  • the interval P2 is preferably not less than 1.5 times and not more than 6 times, more preferably not less than 2 times and not more than 4 times the interval P1.
  • the “arrangement along the vertical direction X” includes not only the case where they are arranged completely along the vertical direction but also the case where they are arranged obliquely from the vertical direction X. That is, it is only necessary that the plurality of dents 86 are arranged apart in the vertical direction X.
  • a depression 86 is formed in a region D (corresponding to a region between the first high-density portions) between the side leakage preventing grooves 81 and 81 shown as a hatched portion in FIG.
  • a plurality of front areas A6, a rear area C6 in which a plurality of depressions 86 are formed, and a central area B6 in which the depressions 86 are not formed are located between the front area A6 and the rear area C6. ing.
  • each depression 86 the skin facing surface side of the absorbent body 4 is recessed in a concave shape together with the surface sheet 2, and the absorbent body 4 is a recess in the absorbent body 4 where the depression 86 is formed. It is consolidated more than the absorber of parts other than 86 and the annular leak-proof groove 8.
  • the depression 86 as the second high-density portion can be formed by, for example, applying embossing with pressurization or heating and pressurization to the superposed sheet 2 and the absorbent body 4.
  • the absorbent body 4 of the napkin 1 has an absorbent core 41 containing pulp fibers and a core wrap sheet 42 that covers the absorbent core 41.
  • the core wrap sheet 42 in this embodiment is wound down to the skin-side portion 42 a that covers the skin-facing surface side of the absorbent core 41 and the non-skin-facing surface side of the absorbent core 41.
  • the core wrap sheet 42 has an overlapping portion 42c between sheets in the lower portion 42b.
  • seat may wrap the whole absorptive core with one sheet, and may wrap the whole absorptive core with two or more sheets.
  • the skin facing surface side and the non-skin facing surface side of the absorbent core 41 may be covered with separate sheets.
  • the core wrap sheet 42 of the present embodiment contains a hemagglutinating agent. More specifically, in the core wrap sheet 42 of the present embodiment, the entire region including the skin side portion 42a and the lower portion 42b is a hemagglutinating agent arrangement portion containing a hemagglutinating agent.
  • the core wrap sheet is used for the purpose of improving the shape retention of the absorbent core, which is insufficient in shape retention by itself, or preventing the leakage of the constituent material of the absorbent core.
  • the fiber sheet is used.
  • a resin film having through holes can also be used.
  • As the core wrap sheet a fiber sheet such as a thin paper or a non-woven fabric is used as a base sheet, and a hemagglutinating agent is held on the base sheet.
  • the resin film which has a through-hole can also be used as a base material sheet.
  • the substrate sheet of the core wrap sheet is preferably a sheet composed of cellulosic fibers.
  • Thin paper is a typical example of a sheet composed of cellulosic fibers.
  • those conventionally used as a core wrap sheet can be used without particular limitation.
  • Thin paper is produced by wet papermaking.
  • Examples of the cellulosic fibers constituting the thin paper include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers.
  • Examples of cellulosic fiber pulp include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or straw pulp. These cellulosic fibers can be used singly or in combination of two or more. Further, from the viewpoint of improving the strength, a small amount of non-cellulosic fibers can be mixed.
  • Examples of non-cellulosic fibers include polyolefin fibers such as polyethylene and polypropylene, and condensation fibers such as polyester and polyamide.
  • the proportion of the cellulosic fibers in the constituent fibers of the thin paper is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • the base sheet of the core wrap sheet of the present embodiment is preferably a sheet composed of cellulosic fibers, and in terms of liquid permeability, hardness, and pore size, the basis weight is preferably It is 10 g / m 2 or more, more preferably 13 g / m 2 or more, preferably 30 g / m 2 or less, more preferably 20 g / m 2 or less.
  • the base sheet of the core wrap sheet 42 of the present embodiment a sheet manufactured mainly by a wet papermaking method is used, but a sheet manufactured by a dry method such as airlaid can also be used.
  • Nonwoven fabric can also be used as the base sheet.
  • nonwoven fabrics produced by various production methods can be used.
  • a spunbond nonwoven fabric a melt blown nonwoven fabric, a spunlace nonwoven fabric which is a nonwoven fabric obtained by entanglement of constituent fibers of a fiber web by high-speed water flow treatment, and a fiber by hot air treatment
  • examples thereof include an air-through non-woven fabric which is a non-woven fabric obtained by heat-sealing the constituent fibers of the web, and a resin bond non-woven fabric which is a non-woven fabric obtained by bonding the constituent fibers of the fiber web with an adhesive.
  • the fiber web of spunlace nonwoven fabric, air-through nonwoven fabric, and resin bond nonwoven fabric can be manufactured by a card machine or an airlaid method in which fibers are stacked in air.
  • Non-woven fabric fibers are made from cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers and cellulose acetate, polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and synthetic resins such as polyamides such as nylon.
  • the synthetic fiber which becomes is mentioned.
  • a core-sheath type or side-by-side type composite fiber may be used.
  • the non-woven fabric is made of cellulosic fibers.
  • the proportion of the cellulosic fibers in the constituent fibers of the nonwoven fabric is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • the raw material fiber of a nonwoven fabric can be used individually by 1 type or in combination of 2 or more types.
  • the absorptive core 41 of the napkin 1 of this embodiment is composed of a mixed product of pulp fibers and a superabsorbent polymer.
  • the mixed fiber stack is manufactured by a known drum-type fiber stacking apparatus including a stacking drum having a stacking concave portion on the peripheral surface, and is sucked from the bottom surface of the stacking concave portion, The surface is supplied with pulp fibers and superabsorbent polymer as the absorbent core forming material in a scattered state, and after the absorbent core forming material is deposited in the accumulation recess, it is released from the accumulation recess. Is obtained.
  • the absorbent core 41 of the napkin 1 of the present embodiment may be a single fiber stack of pulp fibers that does not contain a superabsorbent polymer.
  • Examples of the pulp fibers constituting the absorbent core 41 include cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate. These fibers can be used alone or in combination of two or more.
  • Examples of the raw material pulp of the pulp fiber include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or wall pulp.
  • the absorbent core 41 is made of synthetic fibers such as polyolefin fibers such as polyethylene and polypropylene, condensed fibers such as polyester and polyamide, in addition to pulp fibers made of cellulosic hydrophilic fibers. A small amount may be mixed.
  • the absorbent core in the present invention has a ratio of pulp fibers (cellulosic fibers), particularly wood pulp fibers, of preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less. Preferably it is 100 mass%.
  • the absorptive core 41 may contain the water absorbing polymer.
  • a particulate polymer is generally used, but a fibrous polymer may be used.
  • the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape.
  • a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof.
  • sodium salts can be preferably used.
  • the method for retaining the hemagglutinating agent on the core wrap sheet is not particularly limited as long as it can be retained, but an appropriate solvent such as water, ethanol, or a mixture thereof. It can be dissolved in the solution and adhered or immersed in the base sheet as a solution with various properties such as viscosity adjusted appropriately, and then dried to remove the solvent, and the hemagglutinating agent is buried in the pores of the core wrap sheet 42 It is preferable from the viewpoint of being easily held in a wet state.
  • an appropriate solvent such as water, ethanol, or a mixture thereof. It can be dissolved in the solution and adhered or immersed in the base sheet as a solution with various properties such as viscosity adjusted appropriately, and then dried to remove the solvent, and the hemagglutinating agent is buried in the pores of the core wrap sheet 42 It is preferable from the viewpoint of being easily held in a wet state.
  • the method of adhering the solution containing the hemagglutinating agent to the core wrap sheet includes immersion of the base sheet in the solution, dripping of the solution, spray coating of the solution to the base sheet, dipping method, transfer method, die coating, gravure coating.
  • Various coatings such as coating, inkjet method, screen printing, and the like can be mentioned.
  • the drying may be any of drying by heating, drying by reduced pressure, and drying combining heating and reduced pressure, but may be natural drying instead of forced drying. It is more preferable to dry by heating, particularly within a range where the hemagglutinating agent and the base sheet are not damaged, and by heating at a higher temperature to remove the solvent rapidly.
  • the hemagglutinating agent provided in the napkin 1 acts to agglutinate erythrocytes in blood to form aggregates and separate them from plasma components.
  • a preferred hemagglutinating agent when 1000 ppm is added to simulated blood, at least two or more red blood cells aggregate to form an aggregate in a state where the fluidity of the blood is maintained.
  • Simulated blood means that the viscosity measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) is 8 mPa ⁇ s.
  • the blood cell / plasma ratio of defibrinated horse blood (manufactured by Nippon Biotest Laboratories, Inc.) was prepared.
  • “the state in which the fluidity of blood is maintained” means that 10 g of blood to which a measurement sample is added at 1000 ppm is a screw tube bottle (product number “Screw tube No. 4” manufactured by Maruem Co., Ltd., mouth inner diameter 14.5 mm, body diameter 27 mm, total length 55 mm), and when the screw tube bottle containing the simulated blood is inverted 180 degrees, it means that 80% or more of the menstrual blood simulates within 5 seconds. Further, whether or not “two or more red blood cells aggregate to form an aggregate” is determined as follows.
  • the simulated blood to which the measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring apparatus (manufactured by HORIBA, model number: LA-950V2, measurement condition: flow type).
  • the median diameter of volume average particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using cell measurement, circulation speed 1, no ultrasonic wave) corresponds to the size of an aggregate in which two or more red blood cells are aggregated. If it is 10 ⁇ m or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.
  • the hemagglutinating agent retained in the absorber 4 contains a polycation (cationic polymer).
  • the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride.
  • the hemagglutinating agent can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer.
  • the hemagglutinating agent can also contain a low-molecular natural homopolymer such as polylysine as the cationic polymer.
  • the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution.
  • the “quaternary ammonium moiety” described below is also used in the same meaning and is a moiety that is positively charged in water.
  • the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things.
  • the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.
  • the hemagglutinating agent includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer
  • a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate may be included, or any combination of two or more thereof may be included. Also good.
  • a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types.
  • the quaternary ammonium salt copolymer can be used alone or in combination of two or more.
  • a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.
  • the “hemagglutinating agent” refers to the aggregation of erythrocytes by a single compound or a combination of single compounds capable of aggregating blood erythrocytes or a combination of a plurality of compounds. It is an agent that expresses. That is, the hemagglutinating agent is an agent limited to those having a hemagglutination effect.
  • the hemagglutinating agent contains the third component, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.
  • the term “single compound” is a concept including compounds having the same composition formula but having different molecular weights due to different numbers of repeating units.
  • quaternary ammonium salt polymer a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate
  • quaternary ammonium salt polymer a quaternary ammonium salt polymer that is quaternary ammonium salt of a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt polycondensate.
  • the quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.
  • the quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety.
  • a quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent.
  • the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce
  • the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate.
  • dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur.
  • the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. .
  • a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized.
  • Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.
  • Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • erythrocytes can be treated as colloidal particles having an anionic charge.
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.
  • the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 150,000 or more.
  • the upper limit of the molecular weight is preferably 30 million or less, more preferably 22 million or less, and even more preferably 10 million or less.
  • the molecular weight of the cationic polymer is preferably 2000 or more and 30 million or less, more preferably 10,000 or more and 22 million or less, and further preferably 150,000 or more and 30 million or less.
  • the molecular weight referred to in the present invention is a weight average molecular weight.
  • the molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions.
  • the molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.
  • a column a column in which a guard column ⁇ and an analytical column ⁇ -M manufactured by Tosoh Corporation are connected in series is used at a column temperature of 40 ° C.
  • the detector uses RI (refractive index).
  • 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 ⁇ L.
  • Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 ⁇ L.
  • the quaternary ammonium salt polymer has a flow potential of 1500 ⁇ eq / L or more from the viewpoint of more effectively generating red blood cell aggregates. , More preferably 2000 ⁇ eq / L or more, still more preferably 3000 ⁇ eq / L or more, still more preferably 4000 ⁇ eq / L or more.
  • the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized.
  • the upper limit of the streaming potential is preferably 13000 ⁇ eq / L or less, more preferably 8000 ⁇ eq / L or less, and even more preferably 6000 ⁇ eq / L or less.
  • the streaming potential of the quaternary ammonium salt polymer is preferably 1500 ⁇ eq / L or more and 13000 ⁇ eq / L or less, more preferably 2000 ⁇ eq / L or more and 13000 ⁇ eq / L or less, and 3000 ⁇ eq / L or more and 8000 ⁇ eq / L or less. Is more preferably 4000 ⁇ eq / L or more and 6000 ⁇ eq / L or less.
  • the flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituting cationic monomer itself, and the copolymerization molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. Can be controlled.
  • the streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, hot melt bonding each member to a commercially available napkin is invalidated using a dryer or the like, and decomposed into members such as a top sheet, an absorber, and a back sheet.
  • a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition.
  • the obtained solution was dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent.
  • the cationic polymer In order for the cationic polymer to be successfully adsorbed on the surface of red blood cells, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of red blood cells. From this point of view, the present inventors proceeded with studies, and as a result, inorganic value / organic value (hereinafter referred to as “IOB (Inorganic Organic Balance) value”), which is the ratio between the inorganic value and the organic value of the substance. It was found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of. Specifically, it has been found advantageous to use a cationic polymer having an IOB value that is the same as or close to that of the sialic acid conjugate.
  • the sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.
  • the properties of a substance are largely controlled by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Wals force due to molecular mass and electric affinity due to the polarity of the molecule. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electrical affinity can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to.
  • This idea is a theory well known as “organic conceptual diagram”.
  • Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic.
  • the degree of physical properties due to Van Der Waals force is called ⁇ organic ''
  • the degree of physical properties mainly due to electrical affinity is called ⁇ inorganic ''
  • the physical properties of substances are considered as a combination of “organic” and “inorganic”.
  • one carbon (C) is defined as organic 20
  • the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value.
  • the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values
  • the IOB value of the cationic polymer is determined based on the value.
  • the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated.
  • the IOB value is calculated by the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is ORA, the inorganic value is INA, the organic value of monomer B is ORB, and the inorganic value is INB. There, when the molar ratio of the monomer a / monomer B is M a / M B, IOB value of copolymer is calculated from the following equation.
  • the IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, 2.2 It is still more preferable that it is above. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. More preferably, it is 2.2 or more and 3.0 or less.
  • the IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate.
  • the sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.
  • the organic value itself is preferably 40 or more, more preferably 100 or more, and even more preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, still more preferably 240 or less, and even more preferably 190 or less.
  • the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, still more preferably 100 or more and 240 or less, and still more preferably 130 or more and 190 or less.
  • the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and 250 or more. It is particularly preferred that Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less.
  • the inorganic value is preferably from 70 to 790, more preferably from 90 to 750, even more preferably from 90 to 680, still more preferably from 120 to 680, It is especially preferable that it is 250 or more and 490 or less.
  • x and y satisfy the following formula A when the organic value of the cationic polymer is x and the inorganic value is y.
  • y ax (A)
  • a is preferably 0.66 or more, more preferably 0.93 or more, and even more preferably 1.96 or more.
  • a is preferably 4.56 or less, more preferably 4.19 or less, and even more preferably 3.5 or less.
  • a is preferably a number from 0.66 to 4.56, more preferably from 0.93 to 4.19, and a number from 1.96 to 3.5. Is more preferable.
  • the organic value and the inorganic value of the cationic polymer satisfy the above formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above-mentioned ranges, the cation The functional polymer is likely to interact with the sialic acid conjugate, and the cationic polymer is more easily adsorbed to erythrocytes.
  • the cationic polymer is preferably water-soluble.
  • water-soluble means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mm ⁇ ) and mixed with 50 mL ion-exchanged water at 25 ° C.
  • a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd.
  • the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
  • the cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium moiety is preferably present in the side chain.
  • the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs.
  • bonded at one point means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain.
  • Connected at two or more points means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain.
  • a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto.
  • the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more.
  • the upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less.
  • the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less.
  • the carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included.
  • the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer
  • examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety.
  • a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization are examples of the homopolymer.
  • alkylating agent and the acid are as described above.
  • the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.
  • quaternary ammonium salt homopolymer examples include polyethyleneimine.
  • examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer
  • two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer.
  • a copolymer obtained by the above copolymerization can be used.
  • the quaternary ammonium salt copolymer one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety
  • the copolymer obtained by copolymerizing using 1 or more types of bodies can be used.
  • the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.
  • the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer
  • charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated.
  • Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine.
  • Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds.
  • nonionic polymerizable monomers examples include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate.
  • One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do.
  • a quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).
  • a polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety.
  • a polymerizable monomer having no quaternary ammonium moiety When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed.
  • the functional group capable of hydrogen bonding include —OH, —NH 2 , —CHO, —COOH, —HF, —SH and the like.
  • polymerizable monomers having functional groups capable of hydrogen bonding examples include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl An acrylate etc. are mentioned.
  • hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used.
  • a polymerizable monomer for copolymerization By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced.
  • functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups.
  • polymerizable monomers having functional groups capable of hydrophobic interaction examples include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned.
  • methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. Or it is preferable to adjust so that the streaming potential of a quaternary ammonium salt copolymer may become the value mentioned above. Or it is preferable to adjust so that IOB of a quaternary ammonium salt copolymer may become the value mentioned above.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and even more preferably 56 mol% or less.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate
  • a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used as the polycondensate.
  • Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.
  • the above-described quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or copolymerization method of a vinyl polymerizable monomer.
  • the polymerization method for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.
  • the cationic polymer described in detail above is an example of the above-mentioned “preferable hemagglutinating agent”, and the effect thereof is Japanese Patent Application No. 2015-239286, Japanese Patent Application Laid-Open No. 2016-107100, which is a Japanese publication of the application, and Reference can be made to Examples 1 to 45 described in International Publication No. 2016/093233 pamphlet of the international application based on the priority of the application.
  • the hemagglutinating agent retained in the absorbent body 4 is a composition containing, for example, a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, a skin care agent, etc. (hemagglutinating agent composition) It may be given in the form. Moreover, components other than the cationic polymer that can be contained in the hemagglutinating agent can be used alone or in combination.
  • a solvent water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used.
  • glycerin polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used.
  • flavor the fragrance
  • an antibacterial / deodorant it is polymerized from a cancrinite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used.
  • the skin care agent plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.
  • the proportion of the cationic polymer in the hemagglutinating agent is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less.
  • the proportion of the cationic polymer is preferably 1% by mass to 50% by mass, more preferably 3% by mass to 30% by mass, and even more preferably 5% by mass to 10% by mass. preferable.
  • the hemagglutinating agent is arranged in the absorber 4 in the region D between the side leakage preventing grooves 81 that are the first high-density portions, as shown in FIG.
  • a part of the hemagglutinating agent is dissolved in menstrual blood in the absorbent body 4, and the menstrual blood other than blood cell aggregates and blood cells is dissolved. Separate into parts. The migration of blood cell aggregates is suppressed as compared with the parts other than the blood cells, and much remains in the menstrual blood supply site 11, whereas the part 12 other than the blood cells relatively smoothly moves in the absorber 4. Easy to move.
  • the portion 12 other than the menstrual blood cell is located in the absorber 4 in the region D. Spreads more smoothly.
  • the movement of the liquid beyond the side leakage prevention groove 81 is suppressed by the presence of the side leakage prevention groove 81.
  • the portions other than the red blood cells of menstrual blood diffuse well in the absorbent body 4 in the longitudinal direction X of the napkin, and beyond the side leakage prevention groove 81. Since the movement of the liquid is suppressed, the absorption capacity in a wide range of the absorber 4 can be effectively used while suppressing the occurrence of leakage.
  • the napkin 1 of the present embodiment has a high absorption rate, a large amount of absorption, and excellent leak prevention properties due to such actions, for example, greatly improving the absorption performance without changing the thickness, It is also possible to reduce the thickness while maintaining the absorption performance above a certain level.
  • the hemagglutinating agent is preferably provided between the first high density portions in the excretion portion facing portion B, and particularly preferably provided in the excretion spot portion P. .
  • the first high-density portion is the side leakage prevention groove 81
  • the skin facing surface side of the absorber 4 is the leakage prevention groove that is recessed in a groove shape together with the surface sheet 2.
  • a very small gap exists between the absorber 4 and the top sheet 2 in the first high-density portion, or there is no gap. Accordingly, since the liquid is suppressed from flowing through the gap between the absorbent body 4 and the top sheet 2, the movement of the liquid beyond the first high density portion is further effectively suppressed, and inconveniences such as side leakage occur. Is further prevented.
  • the 2nd high density is the dent 86
  • the skin opposing surface side of the absorber 4 is a dent recessed in the concave shape together with the surface sheet 2, the absorption in the 2nd high density part.
  • the plurality of second high density depressions 86 are arranged in the longitudinal direction X, components other than menstrual blood erythrocytes are absorbed in the absorber 4 in the napkin. It diffuses quickly in the vertical direction X, and thereby, the absorption capacity of a wide range of the absorber 4 can be effectively utilized.
  • the amount of liquid that moves to the first high-density portion decreases, so that the movement of the liquid beyond the first high-density portion is more effective. Inconveniences such as side leakage are further prevented.
  • the absorption speed is fast and the absorption amount is further improved by the cooperative action of the first high-density portion and the second high-density portion.
  • a central region B6 in which the recess 86 is not formed is provided between the front region A6 in which the recess 86 is formed and the rear region C6.
  • the density of fibers in the absorbent body is small, and the movement of the liquid is slow compared to the front area A6 and the rear area C6 in which depressions are formed and the density of fibers in the absorbent body is high. Therefore, in the central region B6, the hemagglutinating agent is effectively dissolved by the excreted blood, and an erythrocyte aggregate can be effectively formed.
  • the central region B6 has a length Lc in the vertical direction X of preferably 3 cm or more and 5 cm or less, more preferably 3 cm or more and 4 cm or less.
  • the skin facing surface side of the absorbent body 4 is recessed with the surface sheet 2 in a concave shape, that is, the above-described recess 86 or the recess thereof. No depression having the same configuration as that of 86 is formed.
  • the top sheet 2 As the top sheet 2, the back sheet 3, and the side leak-proof sheet 6, those normally used for absorbent articles such as sanitary napkins can be used without particular limitation. it can.
  • the surface sheet 2 a hydrophilic and liquid-permeable nonwoven fabric, an apertured film, or the like can be used.
  • the surface sheet 2 can be coated with various oil agents for improving liquid permeability, for example, various surfactants.
  • the topsheet 2 When the topsheet 2 has a multilayer structure, the topsheet 2 includes a first fiber layer located on the side close to the wearer's skin and a second fiber layer located on the side far from the wearer's skin.
  • both fiber layers are integrated in the thickness direction by a number of joints formed in part, and a portion of the first fiber layer located between the joints is convex.
  • a concavo-convex sheet that protrudes and forms the concavo-convex convex portion.
  • the convex portion of the concavo-convex sheet may have a solid structure that is entirely filled with fibers, or may have a hollow structure having a space inside.
  • the concavo-convex sheet in which the convex portion has a solid structure for example, those described in Japanese Patent Application Laid-Open Nos. 2007-182626 and 2002-187228 can be used.
  • a liquid-impermeable or water-repellent resin film, a laminate of a resin film and a nonwoven fabric, or the like can be used.
  • a laminated nonwoven fabric having a high water pressure resistance, a laminate of a resin film and a nonwoven fabric, or the like can be used.
  • the second high-density portion such as the depression 86 described above may be formed in the form shown in FIG. 6 or FIG.
  • the depressions 86 (second high-density portions) in the sanitary napkin 1A shown in FIG. 6 are arranged in a staggered manner. More specifically, the depression rows R6 in which the depressions 86 are arranged in series in the vertical direction X are formed in a plurality of rows in the horizontal direction Y. In the adjacent depression rows R6, the positions of the depressions 86 are a half pitch. It is off.
  • the depressions 86 (second high-density parts) are distributed in the front part A, the excretion part facing part B, and the rear part C, but the central area B6 where the depressions 86 do not exist. Does not have.
  • the side leak-proof groove 81 existed as what comprises a part of cyclic
  • the side leak-proof groove 81 and the front leak-proof groove 82 and the rear leakage prevention groove 83 may be provided, or only a pair of side leakage prevention grooves 81, 81 may be formed on the skin facing surface of the napkin 1.
  • the shape of the pair of side leakage preventing grooves 81, 81 and the pair of first high density portions can be appropriately changed.
  • the shape of the side leakage preventing grooves 81 (first high density portion) in plan view is outward.
  • the arcuate portion convex toward the inner side and the arcuate portion convex toward the inside may be continuous in the longitudinal direction, and the side leakage prevention groove 81 (first high-density portion)
  • a leakage prevention groove composed of only one arcuate portion that is convexly curved inward or inward, or a leakage prevention groove composed of only one linear portion extending in the longitudinal direction may be provided.
  • the hemagglutinating agent is disposed only on the core wrap sheet 42 or mainly on the core wrap sheet 42, but may be disposed only on the absorbent core 41. 42 and the absorbent core 41 may be disposed. Further, instead of disposing the hemagglutinating agent throughout the core wrap sheet 42, it may be disposed only on the skin side portion 42a, and further disposed only on the inner side portion of the annular leakage preventing groove 8 in the skin side portion 42a. Alternatively, it may be disposed only between the pair of side leakage preventing grooves 81, 81.
  • the shape of the second high-density portion in plan view can be an ellipse, an oval, a triangle, a quadrangle, a trapezoid, a pentagon, a star, or the like, instead of a circle.
  • the absorbent article may be one that does not have a side leak-proof sheet and a leak-proof mechanism thereby, or may have no wing portion.
  • the absorbent article of the present invention may be a sanitary napkin, a panty liner (clay sheet), or the like.
  • a menstrual blood having a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorbent body disposed between the two sheets and having a longitudinal direction along the wearer's front-rear direction and a transverse direction perpendicular to the longitudinal direction
  • An absorbent article for absorption wherein the absorbent body has a first high-density portion on each side of a center line that bisects the absorbent article in the transverse direction and extends in the longitudinal direction.
  • a hemagglutinating agent is disposed in the absorber in the region between the first high-density portions, and the absorber has a second high-density portion in the region between the first high-density portions.
  • a part is formed, and the first and second high-density parts are absorbent articles in which the density of the absorber is higher than the density in a part other than the first and second high-density parts.
  • the absorbent article has an excretory part facing part disposed opposite to the excretion part of the wearer when worn along the longitudinal direction, and a front part arranged closer to the front side of the wearer than the excretion part facing part.
  • the rear portion disposed closer to the rear side of the wearer than the excretion portion facing portion, and the excretion portion facing portion has an excretion spot portion, according to ⁇ 1>.
  • Absorbent article. ⁇ 3> The absorptive article according to ⁇ 2>, wherein the hemagglutinating agent is disposed between the first high-density portions in the excretion portion-facing portion.
  • the first high-density portion is the leak-proof groove according to any one of ⁇ 1> to ⁇ 4>, wherein the skin-facing surface side of the absorber is a leak-proof groove that is recessed in a groove shape together with the surface sheet. Goods.
  • ⁇ 6> The absorbent article according to any one of ⁇ 1> to ⁇ 5>, wherein the second high-density portion is a depression in which the skin-facing surface side of the absorber is recessed in a concave shape together with the surface sheet.
  • ⁇ 7> The absorptive article given in the above ⁇ 6> in which a plurality of above-mentioned hollows are arranged along with the above-mentioned lengthwise direction.
  • ⁇ 8> ⁇ 7>, wherein a plurality of depression rows in which the depressions are arranged in series in the vertical direction are formed in the horizontal direction, and the interval between adjacent depression rows is wider than the interval between the depressions in the depression row.
  • ⁇ 9> A plurality of depressions formed in a region between the first high-density portions; a rear region in which a plurality of depressions are formed; and the depressions located between the front region and the rear region.
  • ⁇ 11> Any one of the above items ⁇ 1> to ⁇ 10>, in which the skin facing surface side of the absorber is not formed with a recess that is recessed in a concave shape together with the surface sheet at both ends of the absorber in the longitudinal direction.
  • the area of the second high-density portion is 0.5 mm 2 or more 15 mm 2 or less, preferably is 2 mm 2 or more 5 mm 2 or less, wherein ⁇ 1> to absorbent article according to any one of ⁇ 12>.
  • ⁇ 14> The absorbent article according to any one of ⁇ 8> to ⁇ 13>, wherein an interval between adjacent indentation rows is wider than an interval between indentations in the indentation row.
  • the interval P2 between the adjacent dent rows is 1.5 to 6 times, preferably 2 to 4 times the interval P1 between the dents in the dent rows, ⁇ 8> to ⁇ 14>
  • the side leakage prevention grooves are connected to each other at the front side by a front leakage prevention groove passing through the front side from the excretion spot part, and rearward by a rear leakage prevention groove passing through the rear side from the excretion spot part.
  • ⁇ 18> The absorbent article according to any one of ⁇ 1> to ⁇ 17>, wherein the hemagglutinating agent is a cationic polymer having a weight average molecular weight of 2000 to 30 million.
  • the absorbent body has an absorbent core and a core wrap sheet covered with the absorbent core.
  • ⁇ 21> The absorbent article according to ⁇ 20>, wherein the hemagglutinating agent is contained in the core wrap sheet.
  • ⁇ 22> The absorptive article according to the above ⁇ 21>, wherein the hemagglutinating agent is disposed on a skin side portion on the skin facing surface side of the core wrap sheet.
  • ⁇ 23> The absorbent article according to ⁇ 21>, wherein the hemagglutinating agent is disposed throughout the core wrap sheet.
  • ⁇ 24> The absorbent article according to ⁇ 20>, wherein the hemagglutinating agent is disposed on the core wrap sheet and the absorbent core.
  • ⁇ 25> The absorbent article according to any one of ⁇ 1> to ⁇ 24>, wherein the absorbent article is a sanitary napkin.
  • Example 1 A sanitary napkin having the form shown in FIGS. 1 and 2 was prepared and used as a sample of Example 1.
  • the sanitary napkin had a thickness of 4.2 mm.
  • As the surface sheet 2 a non-woven fabric used in Laurie Skin Clean Guard (normal wings) manufactured by Kao Corporation was used.
  • As the back sheet 3 a non-moisture permeable resin film was used.
  • the absorbent body 4 is configured to wrap the absorbent core 41 from the skin facing surface side to the non-skin facing surface side with a single core wrap sheet 42.
  • the absorbent core 41 contains pulp fibers made of wood pulp, has a fiber single layer not containing a superabsorbent polymer on the skin facing surface side, and has a mixed fiber layer containing a superabsorbent polymer as a single fiber. What was in the layer below the layer was used.
  • the mixed fiber body had a basis weight of wood pulp fibers of 300 g / m 2 and a basis weight of superabsorbent polymer of 56 g / m 2 .
  • As the superabsorbent polymer a general-purpose grade superabsorbent polymer for sanitary goods manufactured by Nippon Shokubai Co., Ltd. was used.
  • a thin paper (tissue paper) having a basis weight of 16 g / m 2 and a thickness of 0.3 mm was used.
  • 5.00 g of the hemagglutinating agent of the following formulation is dissolved in 100 g of ion-exchanged water, and the solution is immersed in the core wrap sheet so as to have a basis weight of 120 g / m 2 , and then the core wrap sheet is placed in a dryer. And dried for 24 hours at 60 ° C., and the hemagglutinating agent contained in the dried core wrap sheet was 6 g / m 2 .
  • polydiallyldimethylammonium chloride which is a water-soluble quaternary ammonium salt homopolymer (trade name Marcoat 100 (weight average molecular weight: 150,000) manufactured by Nippon Lubrizol) was used.
  • a first high-density portion was formed by compressing the absorbent body at 150 ° C. for 1.0 second on the skin facing surface side of the absorbent core.
  • the 2nd high-density part was formed by compressing an absorber on 25 degreeC 1.5 second conditions.
  • the second high density portion of Example 1 was substantially circular.
  • the interval P1 in the vertical direction X between the second high density portions in the recess row R6 is 3.5 mm
  • the interval P2 in the lateral direction Y between the adjacent recess rows R6 and R6 is 10.
  • the distance between the second high-density parts facing in the longitudinal direction X across the central region B6 was 35 mm.
  • the length Lx along the vertical direction X and the length width Ly along the horizontal direction Y of the second high-density portion were set to 2 mm.
  • a sanitary napkin was prepared in the same manner as in Example 1 except that a core wrap sheet that did not retain the hemagglutinating agent was used, and this was used as a sample of Comparative Example 1.
  • the thickness of the sanitary napkin was 4.2 mm.
  • Example 1 Sanitary Napkin
  • Comparative Example 1 Sanitary Napkin
  • Reference Example Sanitary Napkin
  • a sample of a sanitary napkin was fixed to a sanitary short and attached to a dynamic model of the human body.
  • the walking motion of the dynamic model was started, and 1 g after the start of the walking motion, 2 g of pseudo blood was injected from the excretion spot portion P (first time). Furthermore, 3 g of simulated blood was injected 3 minutes after the end of the first liquid injection (second time). Furthermore, 2 g of simulated blood was injected 3 minutes after the end of the second liquid injection (third time).
  • the third and subsequent liquid injections were repeatedly injected with 2 g of pseudo blood 3 minutes after the liquid injection, and ended when the liquid oozed out from the wing part of the sanitary napkin, and the dynamic maximum absorption amount was obtained.
  • a sanitary napkin was fixed to the experimental table, and an acrylic plate having a cylindrical tube having a hole with a diameter of 10 mm was placed on the top sheet.
  • 3 g of pseudo blood was injected into a cylindrical tube facing the excretion spot P and allowed to stand for 3 minutes. Thereafter, the length of the pseudo blood diffusing in the lateral and longitudinal directions of the napkin is measured, and the ratio of the longitudinal diffusion length to the lateral diffusion length is calculated, and this is used as the liquid diffusion length aspect ratio. .
  • the sanitary napkin of Example 1 has a dynamic maximum absorption amount of Comparative Example 1 in which no hemagglutinating agent is used, and Reference Example in which the second high-density portion is not formed. More than.
  • the diffusion of menstrual blood from the liquid excretion part in the lateral direction is suppressed as compared with the sanitary napkin of Comparative Example 1. It can be seen that the amount of liquid diffusing in the vertical direction increases. Therefore, liquid leakage from the lateral direction is suppressed, and the dynamic maximum absorption amount is increased.
  • the sanitary napkin of Example 1 has improved menstrual blood diffusion length compared to the sanitary napkin of the reference example.
  • the sanitary napkin of the reference example has an improved dynamic maximum absorption amount compared with the sanitary napkin of the comparative example 1, and the liquid leakage suppression effect is good, but the sanitary napkin of the example 1 is more liquid. Excellent leakage improvement effect.
  • the absorbent article of the present invention is superior in the amount of menstrual blood absorbed.
  • an absorbent article that effectively exhibits the effect of improving the absorption performance by the hemagglutinating agent, has a large amount of absorption, and is excellent in leakage prevention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

La présente invention concerne un article absorbant (1) destiné à l'absorption du saignement menstruel qui est prévu avec une feuille avant perméable aux liquides (2), une feuille arrière imperméable aux liquides (3), et un corps absorbant (4) disposé entre les feuilles avant et arrière, et qui présente un sens longitudinal (X) et un sens transversal (Y), dans le corps absorbant (4), une première section de haute densité (81) est formée s'étendant dans le sens longitudinal sur les deux côtés de la ligne centrale (CL) de l'article absorbant (1) s'étendant dans le sens longitudinal (X), un coagulant sanguin est disposé dans le corps absorbant (4) dans une région (D) située entre les premières sections de haute densité, les secondes sections de haute densité (86) sont formées dans la région (D) entre les premières sections de haute densité, et la densité du corps absorbant (4) dans les premières et les secondes sections de haute densité (81), (86) est supérieure à la densité dans les sites extérieurs aux premières et secondes sections de haute densité (81), (86).
PCT/JP2017/019964 2016-06-03 2017-05-29 Article absorbant Ceased WO2017209069A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-112111 2016-06-03
JP2016112111A JP2017217101A (ja) 2016-06-03 2016-06-03 吸収性物品

Publications (1)

Publication Number Publication Date
WO2017209069A1 true WO2017209069A1 (fr) 2017-12-07

Family

ID=60477823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/019964 Ceased WO2017209069A1 (fr) 2016-06-03 2017-05-29 Article absorbant

Country Status (2)

Country Link
JP (1) JP2017217101A (fr)
WO (1) WO2017209069A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4039238A4 (fr) * 2019-10-28 2022-11-23 Zuiko Corporation Absorbeur et couche jetable pourvue de celui-ci

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2007089907A (ja) * 2005-09-29 2007-04-12 Kao Corp 吸収性物品
JP2010148708A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 薄型吸収性物品
JP2011520532A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー カチオン性化工デンプンを含む吸収性製品
JP2011529772A (ja) * 2008-08-08 2011-12-15 ザ プロクター アンド ギャンブル カンパニー カチオン性変性グアーガムを含む吸収性製品
JP2013040434A (ja) * 2011-07-19 2013-02-28 Kao Corp 薄葉紙の製造方法
JP2014068991A (ja) * 2012-10-01 2014-04-21 Kao Corp 吸収性物品

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2007089907A (ja) * 2005-09-29 2007-04-12 Kao Corp 吸収性物品
JP2011520532A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー カチオン性化工デンプンを含む吸収性製品
JP2011529772A (ja) * 2008-08-08 2011-12-15 ザ プロクター アンド ギャンブル カンパニー カチオン性変性グアーガムを含む吸収性製品
JP2010148708A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 薄型吸収性物品
JP2013040434A (ja) * 2011-07-19 2013-02-28 Kao Corp 薄葉紙の製造方法
JP2014068991A (ja) * 2012-10-01 2014-04-21 Kao Corp 吸収性物品

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4039238A4 (fr) * 2019-10-28 2022-11-23 Zuiko Corporation Absorbeur et couche jetable pourvue de celui-ci
US20220370263A1 (en) * 2019-10-28 2022-11-24 Zuiko Corporation Absorber and disposable diaper equipped with same

Also Published As

Publication number Publication date
JP2017217101A (ja) 2017-12-14

Similar Documents

Publication Publication Date Title
JP2017217465A (ja) 吸収性物品
WO2017209071A1 (fr) Article absorbant
JP6259540B2 (ja) 生理用吸収性物品
TWI716514B (zh) 吸收性物品
WO2017209068A1 (fr) Article absorbant
JP2018007705A (ja) 生理用吸収性物品
JP6228629B1 (ja) 吸収性物品
JP6279015B2 (ja) 吸収性物品
JP2017217069A (ja) 生理用吸収性物品
WO2017209069A1 (fr) Article absorbant
JP2017217466A (ja) 吸収性物品
WO2017209076A1 (fr) Article absorbant hygiénique
JP6887878B2 (ja) 吸収性物品
JP6762142B2 (ja) 吸収性物品
CN108778206A (zh) 吸收性物品
WO2017110716A1 (fr) Article absorbant
JP2019041794A (ja) 吸収性物品
JP6220947B1 (ja) 生理用品
JP6228630B1 (ja) 血球凝集性繊維
WO2017209072A1 (fr) Article absorbant
JP2017217104A (ja) 吸収性物品
JP6669595B2 (ja) 吸収性物品
JP6757601B2 (ja) 生理用吸収性物品
JP6714435B2 (ja) 生理用吸収性物品
WO2017209074A1 (fr) Article absorbant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17806624

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17806624

Country of ref document: EP

Kind code of ref document: A1